...
首页> 外文期刊>Cancer chemotherapy and pharmacology. >Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.
【24h】

Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models.

机译:N-乙酰半胱氨酸给药途径对大鼠模型化学保护对顺铂诱导的毒性的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dosing and route of administration of N-acetylcysteine (NAC) for protection against cisplatin (CDDP) nephrotoxicity was investigated in rats. Two models of toxicity were tested: a single high dose of CDDP (10 mg/kg intraperitoneally (IP)), and multiple low dose treatments (1 mg/kg IP twice a day for 4 days, 10 days rest, then repeated). NAC (50-1,200 mg/kg) was given to the rats by IP, oral (PO), intravenous (IV) and intra-arterial (IA) routes. Renal toxicity was determined by blood urea nitrogen (BUN) and creatinine (CR) levels 3 days after treatment. Blood collected 15 min after NAC was analyzed for total NAC. Both models of CDDP administration produced renal toxicity. In the single dose CDDP model, NAC 400 mg/kg given IP and PO produced no renal protection as measured by BUN (131.8 +/- 8.2 and 123.3 +/- 8.2, respectively) or CR (2.3 +/- 0.38 and 1.77 +/- 0.21, respectively). IV NAC reduced nephrotoxicity, (BUN 26.3 +/- 6.8, CR 0.47 +/- 0.15). NAC 50 mg/kg IA gave better protection than IV. In the repeated-dose CDDP model, nephrotoxicity was blocked by 800 mg/kg NAC given IV but not IP. Blood concentrations of total NAC showed a dose response after IV NAC, but high dose NAC (1,200 mg/kg) by the PO route gave very low levels of NAC. Thus the protective properties of NAC are affected by the dose and route of administration.
机译:在大鼠中研究了N-乙酰半胱氨酸(NAC)的剂量和给药途径以保护顺铂(CDDP)肾毒性。测试了两种毒性模型:单次高剂量CDDP(腹膜内(IP)10 mg / kg)和多次低剂量治疗(1 mg / kg IP每天两次,连续4天,休息10天,然后重复)。通过IP,口服(PO),静脉(IV)和动脉内(IA)途径给大鼠NAC(50-1,200 mg / kg)。治疗后第3天,通过血液尿素氮(BUN)和肌酐(CR)水平确定肾脏毒性。 NAC 15分钟后收集的血液进行了总NAC分析。两种CDDP给药模型均产生肾毒性。在单剂量CDDP模型中,按BUN(分别为131.8 +/- 8.2和123.3 +/- 8.2)或CR(2.3 +/- 0.38和1.77 + /-分别为0.21)。 IV NAC降低了肾毒性(BUN 26.3 +/- 6.8,CR 0.47 +/- 0.15)。 NAC 50 mg / kg IA比IV具有更好的保护作用。在重复剂量CDDP模型中,静脉给予800 mg / kg NAC可以阻断肾毒性,而IP则不能。总NAC的血液浓度在静脉内NAC后显示出剂量反应,但通过PO途径的高剂量NAC(1200 mg / kg)产生的NAC水平非常低。因此,NAC的保护特性受给药剂量和途径的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号